Earlier we mentioned (Introduction section) that the currently available SMO protein inhibitor Cyclopamine or its closed derivative drug Vismodegib were only effective in the suppression of hedgehog pathway activation in cancer cell, where the pathway was abnormally activated by mutation in SMO or by the over expressions of hedgehog ligands SHH, DHH and/or IHH. The gene discussed is DHH; the disease is cancer.